A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren's disease, with a dose response

Trial Profile

A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren's disease, with a dose response

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2018

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Dupuytren's contracture
  • Focus Pharmacodynamics
  • Most Recent Events

    • 31 Jul 2018 According to 180 Therapeutics media release, results from this tudy were published in the journal EBioMedicine, published by The Lancet.
    • 31 Jul 2018 According to 180 Therapeutics media release, Based on these clinical Phase 2a findings of this study is now supporting a Phase 2b part of this study, which will assess efficacy to retard disease progression over 18 months.
    • 31 Jul 2018 Results published in 180 Therapeutics Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top